[Features of the management of patients during changing the drugs that affect proprotein convertase subtilisin/kexin type 9 (PCSK9)]
{{output}}
It is of interest to study a possibility of switching a patient from one class of lipid-lowering drugs, inhibitors of proprotein convertase subtilisin/kexin type 9 (iPCSK9), to another (inclisiran), when the patient has already reached the target level of low-... ...
